As expected, Celgene Corp. finished its rolling new drug application for Revlimid, asking for the FDA's approval based on Phase II data with the compound for myelodysplastic syndromes (MDS) in transfusion-dependent patients with a 5q-deletion chromosomal abnormality. (BioWorld Today)

The path to market for Genelabs Technologies Inc.'s lupus drug Prestara narrowed this week when another Phase III trial failed to meet the primary endpoint. (BioWorld Today)